Efficacy of Zoledronic Acid in Osteoporosis

Shinshu University100 enrolled

Overview

There has been no comparative data between Zoledronic acid and Zoledronic acid combined with active vitamin D in primary and secondary osteoporosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

100

Conditions

Osteoporosis

Interventions

"Zoledronic acid", "Reclast®"DRUG

To examine the efficacy of zoledronic acid in osteoporosis

"Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®"DRUG

To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Osteoporotic patients who want to take zoledronic acid Exclusion Criteria: * Patients who are allergic to zoledronic acid or vitamin D * Patients who are pregnant or breast-feeding * Patients who have not taken zoledronic acid for the last 2 years

Locations (1)

Yukio Nakamura

Matsumoto, Nagano, Japan

RECRUITING

Outcomes

Primary Outcomes

Bone mineral density

Time frame: Change from Baseline Values at 1 year

Central Contacts

Yukio Nakamura, MD, PhD

CONTACT

+81-263-37-2659 yxn14@aol.jp

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.